Free Trial
NYSEAMERICAN:LCTX

Lineage Cell Therapeutics (LCTX) Stock Price, News & Analysis

Lineage Cell Therapeutics logo
$1.53 -0.02 (-1.29%)
Closing price 09/19/2025 04:10 PM Eastern
Extended Trading
$1.52 -0.01 (-0.39%)
As of 09/19/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Lineage Cell Therapeutics Stock (NYSEAMERICAN:LCTX)

Advanced

Key Stats

Today's Range
$1.46
$1.58
50-Day Range
$0.94
$1.55
52-Week Range
$0.37
$1.62
Volume
1.86 million shs
Average Volume
1.34 million shs
Market Capitalization
$349.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.25
Consensus Rating
Buy

Company Overview

Lineage Cell Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
41st Percentile Overall Score

LCTX MarketRank™: 

Lineage Cell Therapeutics scored higher than 41% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Lineage Cell Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.

  • Upside Potential

    Lineage Cell Therapeutics has a consensus price target of $4.25, representing about 177.8% upside from its current price of $1.53.

  • Amount of Analyst Coverage

    Lineage Cell Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Lineage Cell Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Lineage Cell Therapeutics are expected to grow in the coming year, from ($0.12) to ($0.09) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Lineage Cell Therapeutics is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Lineage Cell Therapeutics is -8.50, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Lineage Cell Therapeutics has a P/B Ratio of 4.37. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Lineage Cell Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    16.18% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Lineage Cell Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Lineage Cell Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    16.18% of the float of Lineage Cell Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Lineage Cell Therapeutics has a short interest ratio ("days to cover") of 11.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Lineage Cell Therapeutics has recently increased by 1.08%, indicating that investor sentiment is decreasing.
  • Search Interest

    42 people have searched for LCTX on MarketBeat in the last 30 days. This is an increase of 250% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Lineage Cell Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Lineage Cell Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    26.80% of the stock of Lineage Cell Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    62.47% of the stock of Lineage Cell Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Lineage Cell Therapeutics' insider trading history.
Receive LCTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lineage Cell Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

LCTX Stock News Headlines

Stunning new initiative unfolding in the White House?
what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for yourself. Once you see what’s unfolding behind the scenes, you’ll understand why I rushed this interview and opportunity to you today.tc pixel
See More Headlines

LCTX Stock Analysis - Frequently Asked Questions

Lineage Cell Therapeutics' stock was trading at $0.5150 at the start of the year. Since then, LCTX stock has increased by 197.1% and is now trading at $1.53.

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) posted its quarterly earnings results on Thursday, August, 8th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.04) by $0.01. The business earned $1.41 million during the quarter, compared to the consensus estimate of $1.28 million. Lineage Cell Therapeutics had a negative trailing twelve-month return on equity of 20.00% and a negative net margin of 374.84%.
Read the conference call transcript
.

Top institutional shareholders of Lineage Cell Therapeutics include Defender Capital LLC. (2.97%), Raffles Associates LP (2.36%), Geode Capital Management LLC (1.06%) and Y Intercept Hong Kong Ltd (0.18%). Insiders that own company stock include Broadwood Partners, LP, Brian M Culley, Don M Bailey and Jill Ann Howe.
View institutional ownership trends
.

Shares of LCTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Lineage Cell Therapeutics investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Meta Platforms (META), Moderna (MRNA), JPMorgan Chase & Co. (JPM) and Chevron (CVX).

Company Calendar

Last Earnings
8/08/2024
Today
9/21/2025
Next Earnings (Estimated)
11/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSEAMERICAN
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSEAMERICAN:LCTX
CIK
876343
Employees
60
Year Founded
N/A

Price Target and Rating

High Price Target
$9.00
Low Price Target
$2.00
Potential Upside/Downside
+177.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.12)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$18.61 million
Net Margins
-374.84%
Pretax Margin
-373.45%
Return on Equity
-20.00%
Return on Assets
-12.93%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.08
Quick Ratio
4.08

Sales & Book Value

Annual Sales
$9.50 million
Price / Sales
36.78
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.35 per share
Price / Book
4.37

Miscellaneous

Outstanding Shares
228,360,000
Free Float
167,157,000
Market Cap
$349.39 million
Optionable
Not Optionable
Beta
1.66
7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NYSEAMERICAN:LCTX) was last updated on 9/21/2025 by MarketBeat.com Staff
From Our Partners